Methscopolamine Bromide
NDC Package 18754-062-06

View Billable Units, 11-Digit Conversion Format, and RxNorm mappings
Table of Contents
    1. Package Information
    2. Frequently Asked Questions

Package Information

This product is EXCLUDED from the official NDC directory because the listing data was discontinued by the firm.

Methscopolamine Bromide is methscopolamine is used with other drugs to treat a certain type of stomach/intestinal ulcer (peptic ulcer). Marketed by Fougera Pharmaceuticals Inc., this product is identified by NDC 18754-062 and is authorized under FDA application NDA008848.

Identification & Billing

NDC Package Code
18754-062-06
Package Description
5 BLISTER PACK in 1 CARTON / 12 TABLET in 1 BLISTER PACK
Product Code
18754-062
11-Digit Billing Format
18754006206

Clinical Specifications

Proprietary Name
Methscopolamine Bromide
Dosage Form
-
Usage Information
Methscopolamine is used with other drugs to treat a certain type of stomach/intestinal ulcer (peptic ulcer). This medication may help relieve stomach/abdominal pain. However, it has not been shown to be effective in healing these ulcers, preventing them from returning, or preventing other problems caused by ulcers. Methscopolamine works by decreasing the amount of acid in the stomach. It also slows the natural movements of the gut and relaxes the muscles in the stomach/intestines. Methscopolamine belongs to a class of drugs known as anticholinergics.

Regulatory & Marketing

Labeler Name
Fougera Pharmaceuticals Inc.
FDA Application #
NDA008848
Marketing Category
NDA - A product marketed under an approved New Drug Application.
Start Marketing Date
10-22-2009
End Marketing Date
12-31-2013
Listing Expiration
12-31-2013
Exclude Flag
D
Sample Package
No

Hierarchy Structure

Code Lineage

The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.

* Please review the full disclaimer at the bottom of this page.

Frequently Asked Questions

What is the distribution configuration for this product package?

The code 18754-062-06 identifies a specific commercial package of 5 blister pack in 1 carton / 12 tablet in 1 blister pack of Methscopolamine Bromide, labeled by Fougera Pharmaceuticals Inc.. This is formulated for use and contains as the active substance.

Is this product currently listed with the FDA?

This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Fougera Pharmaceuticals Inc. on October 22, 2009. The current certification is valid through December 31, 2013.

What are the primary indications for this medication?

Methscopolamine is used with other drugs to treat a certain type of stomach/intestinal ulcer (peptic ulcer). This medication may help relieve stomach/abdominal pain. However, it has not been shown to be effective in healing these ulcers, preventing them from returning, or preventing other problems caused by ulcers. Methscopolamine works by decreasing the amount of acid in the stomach. It also slows the natural movements of the gut and relaxes the muscles in the stomach/intestines. Methscopolamine belongs to a class of drugs known as anticholinergics.

How is this Fougera Pharmaceuticals Inc. product billed for insurance claims?

For medical billing and reimbursement, this package follows the 11-digit CMS format: 18754006206. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.

11-Digit Code Conversion

Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:

10-Digit Format (5-3-2)
18754-062-06
11-Digit CMS (5-4-2)
18754-0062-06

Note: The zero is added to the Product segment to maintain the 5-4-2 structure.